Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV multicenter study of dupilumab in Chinese children and adolescents with moderate-to-severe atopic dermatitis
CTR20232209Phase 4Completed
- Sponsor
- Sanofi
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of dupilumab in atopic dermatitis (AD), sponsored by Sanofi. Started Aug 2023; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20232209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232209.